AptaC – Aptamers and fusion aptamers binding haemostatic molecules for diagnostic and therapeutic use
Activated protein C (APC) plays a key role in vascular and inflammatory diseases. As endogenous inhibitor APC inactivates blood clotting factors Va and VIIIa controlling plasmatic haemostasis.
The inventions provide aptamers as diagnostic tools for detection of APC in biological samples also in the presence of abundant inactive protein C with high selective specificity. This allows establishment of routine diagnostics for APC to analyse disturbances in haemostasis, e.g. in sepsis or in haemophilia A. Further the inventions provide therapeutic aptamers binding to APC for the control of bleeding events, e.g. in haemophilia A or Willebrand syndrome.
Further Information: PDF
Phone: +49 (0)208/94105 0
Dipl.-Ing. Alfred Schillert
Alle Nachrichten aus der Kategorie: Technology Offerings
New calculation refines comparison of matter with antimatter
Theorists publish improved prediction for the tiny difference in kaon decays observed by experiments. -An international collaboration of theoretical physicists–including scientists from the U.S. Department of Energy’s (DOE) Brookhaven National…